Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
about
Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applicationsA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesCharacterization of Amyloid-β Deposits in Bovine BrainsDetermination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry.Identifying and validating biomarkers for Alzheimer's disease.γ-Secretase processing and effects of γ-secretase inhibitors and modulators on long Aβ peptides in cells.Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide poolImmunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.Current state and future directions of neurochemical biomarkers for Alzheimer's disease.Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry.Proteomic research in psychiatry.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.Use of proteomic methods in the analysis of human body fluids in Alzheimer research.Structure-dependent effects of amyloid-β on long-term memory in Lymnaea stagnalis.Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia.
P2860
Q26995267-18157EC9-2FB3-4DD0-A979-34CDEA119C1AQ27010785-848C7616-66BC-4993-A5A5-C4FE76080451Q28597085-9421F403-545D-40FE-B92D-AEC645BFED7FQ33743933-F6FCFAFC-EF86-45E6-9997-1C3F04E7A77EQ34468961-EB30CA1F-4CE7-4186-A127-1D38F63781C2Q35071626-836C3F72-65F9-417B-AEAF-2C8DC0C58E3AQ36347659-C0FEA894-0E44-4892-B078-53832BF22D60Q36484413-A037635C-3F03-4D4D-BDFC-27A97E26361AQ36787240-A8F83BD7-BF22-46F8-8838-9F6D949A9339Q36985933-D9135754-78B9-4B94-9EDA-41787F4F4202Q37157835-6AADF5F3-FE9F-4592-A27B-305F355863D7Q37287652-6AA8A5EB-0295-47CA-811D-E30089366CFBQ37689362-1CB62697-4DD3-4D06-94DC-C0F4F07D3321Q37895052-035653AE-F442-46D1-B9FF-7895D6FA2C03Q38060574-BA3A600F-B99C-4AB7-8493-3A1A031C86C7Q41896658-FCCD6077-236D-499C-BC60-572B7BF431ECQ45420612-578D0C9F-2292-4214-A5D4-64F72DA26187
P2860
Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cerebrospinal fluid profile of ...... by protein biochip technology.
@ast
Cerebrospinal fluid profile of ...... by protein biochip technology.
@en
type
label
Cerebrospinal fluid profile of ...... by protein biochip technology.
@ast
Cerebrospinal fluid profile of ...... by protein biochip technology.
@en
prefLabel
Cerebrospinal fluid profile of ...... by protein biochip technology.
@ast
Cerebrospinal fluid profile of ...... by protein biochip technology.
@en
P2093
P2860
P356
P1476
Cerebrospinal fluid profile of ...... by protein biochip technology.
@en
P2093
Alessia S Maddalena
Andreas Papassotiropoulos
Andri Signorell
Charo Gonzalez-Agosti
Christoph Hock
Roger M Nitsch
Thomas Hegi
Thomas Pasch
P2860
P304
P356
10.1159/000080991
P577
2004-01-01T00:00:00Z